LRIG1 Protein, Mouse, Recombinant (His)

Catalog No. TMPY-02264

Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) is a tumor suppressor and a negative regulator of several receptor tyrosine kinases. Leucine-rich repeats and immunoglobulin-like domains containing protein 1 (LRIG1) is an endogenous feedback regulator of receptor tyrosine kinases (RTKs) and was recently shown to inhibit the growth of different types of malignancies. Leucine-rich repeats and immunoglobulin-like domains 1(LRIG1)is a kind of transmembrane glycoprotein, which is induced by epidermal growth factor (EGF) and develops inhibitory negative feedback by specific binding with epidermal growth factor receptor (EGFR). LRIG1 expression is broadly decreased in human cancer and breast cancer and low expression of LRIG1 has been linked to decreased relapse-free survival.

LRIG1 Protein, Mouse, Recombinant (His)

Catalog No. TMPY-02264

Pack Size	Price	Availability	Quantity
50 μg	$275	7-10 days
500 μg	$1,790	7-10 days

Bulk & Custom

Add to Cart

Questions

Resource Download

User Guide of Recombinant Proteins

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Information

Biological Activity	Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
Description	Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) is a tumor suppressor and a negative regulator of several receptor tyrosine kinases. Leucine-rich repeats and immunoglobulin-like domains containing protein 1 (LRIG1) is an endogenous feedback regulator of receptor tyrosine kinases (RTKs) and was recently shown to inhibit the growth of different types of malignancies. Leucine-rich repeats and immunoglobulin-like domains 1(LRIG1)is a kind of transmembrane glycoprotein, which is induced by epidermal growth factor (EGF) and develops inhibitory negative feedback by specific binding with epidermal growth factor receptor (EGFR). LRIG1 expression is broadly decreased in human cancer and breast cancer and low expression of LRIG1 has been linked to decreased relapse-free survival.
Species	Mouse
Expression System	HEK293 Cells
Tag	C-His
Accession Number	P70193
Synonyms	LIG-1,leucine-rich repeats and immunoglobulin-like domains 1,Img,D6Bwg0781e
Construction	A DNA sequence encoding the extracellular domain of mouse LRIG1 (NP_032403.2) (Met 1-Thr 794) was expressed, with a polyhistidine tag at the C-terminus. Predicted N terminal: Ala 35
Protein Purity	> 95 % as determined by SDS-PAGE
Molecular Weight	85 kDa (predicted); 90-100 kDa (reducing condition, due to glycosylation)
Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, Lyophilized powders are shipping with blue ice.
Research Background	Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) is a tumor suppressor and a negative regulator of several receptor tyrosine kinases. Leucine-rich repeats and immunoglobulin-like domains containing protein 1 (LRIG1) is an endogenous feedback regulator of receptor tyrosine kinases (RTKs) and was recently shown to inhibit the growth of different types of malignancies. Leucine-rich repeats and immunoglobulin-like domains 1(LRIG1)is a kind of transmembrane glycoprotein, which is induced by epidermal growth factor (EGF) and develops inhibitory negative feedback by specific binding with epidermal growth factor receptor (EGFR). LRIG1 expression is broadly decreased in human cancer and breast cancer and low expression of LRIG1 has been linked to decreased relapse-free survival.